7,762 results match your criteria: "Seminoma"
Curr Opin Urol
December 2024
Department of Urology, Cantonal Hospital of Lucerne, Lucerne.
Purpose Of Review: Chemotherapy offers excellent long-term survival rates for men with clinical stage II germ cell tumours. However, in this predominantly younger population, chemotherapy is associated with long-term adverse effects. Primary retroperitoneal lymph node dissection (RPLND) may serve as an alternative treatment option, preserving oncological safety while potentially reducing adverse effects in men with limited retroperitoneal disease.
View Article and Find Full Text PDFSci Rep
December 2024
Clinical Molecular Genetics and Epigenetics, Faculty of Health, Centre for Biomedical Education & Research (ZBAF), Witten/Herdecke University, Alfred-Herrhausen-Str. 50, 58448, Witten, Germany.
Testicular cell differentiation is a highly regulated process, essential for male reproductive health. The histone variant H3.5 is apparently a critical player in this intricate orchestra of cell types, but its regulation and function remains poorly understood.
View Article and Find Full Text PDFCureus
November 2024
Urology, Broward Health Coral Springs, Coral Springs, USA.
Testicular cancer is one of the leading malignancies affecting young men, with germ cell tumors (GCTs) being the most prevalent type. These tumors are classified into two main subtypes: seminomas and non-seminomatous germ cell tumors (NSGCTs), with the latter known for their higher likelihood of metastasis. Early detection through imaging and tumor markers like alpha-fetoprotein (AFP) and beta-human chorionic gonadotropin (HCG) is crucial for favorable outcomes.
View Article and Find Full Text PDFTransl Cancer Res
November 2024
Division of Urologic Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.
Testicular cancer is the most commonly diagnosed cancer among young men in the United States. Seminoma comprises a little over half of all testicular germ cell neoplasms. After radial inguinal orchiectomy, management of seminoma is dictated by tumor stage and risk stratification.
View Article and Find Full Text PDFRev Med Liege
December 2024
Service d'Urologie. CHU Liège, Belgique.
We report the case of a 39-year-old patient who complains about loss of libido and erectile dysfunction. Hormonal diagnosis revealed hypergonadotropic hypogonadism suggesting a primitive testicular cause. Testicular examination, testicular ultrasounds and abdomen-pelvis CT scan made it possible to suspect a right testicular tumor.
View Article and Find Full Text PDFRadiol Case Rep
February 2025
Department of Radiology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Seminoma is a malignant germ cell tumor that primarily develops in the testis but can occur in other extragonadal areas, most commonly the mediastinum and retroperitoneum. While generally offering a favorable prognosis, seminomas can sometimes clinically present with misleading characteristics resulting in delayed diagnosis. In this article, we report the case of a 31-year-old male diagnosed with grade IIIC intermediate risk testicular seminoma cTxN3M1bSx, who presented initially with a palpable cervical mass.
View Article and Find Full Text PDFJ Clin Med
December 2024
Division of Urology, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ 08901, USA.
Urology
December 2024
Sexual & Reproductive Medicine Program, Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Objectives: To evaluate outcomes of onco-testis sperm extraction (TESE) and to define potential predictors of successful surgical sperm retrieval (SSR).
Methods: For this study, we examined all men (i) diagnosed with a testicular mass, (ii) who had azoospermia, and (iii) who underwent a radical orchiectomy and onco-TESE. Our institutional database of testicular cancer (TCA) patients was reviewed.
Pathol Res Pract
November 2024
Department of Histology and Cytophysiology, Medical University of Białystok, Białystok, Poland. Electronic address:
Testicular cancer accounts for approximately 5 % of all urologic cancers. The most common histopathological diagnosis of testicular neoplastic lesions are germ cell tumors (90-95 % of cases), among which the majority of cases are seminomas, the most common malignant tumors among men aged 15-44. For better clinical diagnosis and treatment, it is important to understand the molecular mechanisms of tumor formation.
View Article and Find Full Text PDFCureus
November 2024
Internal Medicine, Rutgers University New Jersey Medical School, Newark, USA.
A 30-year-old Hispanic male was admitted to the medicine service for a growing left testicular and pan-abdominal mass. His prior medical and surgical history was unremarkable. CT imaging showed a retroperitoneal and intraperitoneal mass.
View Article and Find Full Text PDFJ Ayub Med Coll Abbottabad
January 2024
Lahore Medical and Dental College, Lahore-Pakistan.
Front Oncol
November 2024
Medical Oncology Unit, Department of Systems Medicine, University Tor Vergata, Rome, Italy.
The treatment of patients affected by a teratoma with somatic-type malignancy (STM) is challenging, since they are characterized by a poor prognosis, due to chemoresistance to standard cisplatin-based regimens. Only five more case reports were described for melanomatous STM and for which there are no data available for efficacy evidences of immune checkpoint inhibitors in this setting. Here we report the case of a patient with an initial diagnosis of mediastinal pure seminoma at the first biopsy.
View Article and Find Full Text PDFRev Med Suisse
November 2024
Service d'urologie, Centre hospitalier universitaire vaudois, 1011 Lausanne.
Fr J Urol
November 2024
Comité de Cancérologie de l'Association Française d'Urologie, groupe organes génitaux externes, Maison de l'Urologie, 11, rue Viète, 75017 Paris, France; Sorbonne University, GRC 5 Predictive Onco-Uro, AP-HP, Urology, Pitié-Salpêtrière Hospital, 75013 Paris, France.
Cell Commun Signal
November 2024
Department of Urology, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China.
Radiother Oncol
January 2025
Department of Radiotherapy, Institut Bergonié, Bordeaux, France; Centre de Radiothérapie Charlebourg, La Défense, Groupe Amethyst, 65, avenue Foch, 92250 La Garenne-Colombes, France.
J Med Case Rep
November 2024
Department of Medical Oncology, La Fe University and Polytechnic Hospital, Valencia, Spain.
Rev Med Inst Mex Seguro Soc
July 2024
Instituto Mexicano del Seguro Social, Hospital General de Zona No. 47, Servicio de Medicina Interna, Ciudad de México, México.
Neurohospitalist
September 2024
Neurology Department, University of Illinois, Peoria, IL, USA.
Cell Death Dis
November 2024
Department of Oncology, Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 201900, PR China.
Am J Clin Pathol
November 2024
Department of Pathology, The Ohio State University Wexner Medical Center, Columbus, OH, US.
Ann Thorac Surg
November 2024
Division of Thoracic Surgery, Department of Surgery, Massachusetts General Hospital, Boston, MA, USA. Electronic address: